Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 6,471 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 6,471 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $109,101.06. Following the completion of the transaction, the insider now owns 54,322 shares of the company’s stock, valued at $915,868.92. The trade was a 10.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Centessa Pharmaceuticals Trading Down 2.9 %

Shares of CNTA stock traded down $0.49 during trading hours on Tuesday, reaching $16.41. 461,939 shares of the stock were exchanged, compared to its average volume of 593,205. Centessa Pharmaceuticals plc has a 12-month low of $7.38 and a 12-month high of $18.97. The company’s 50-day moving average price is $16.76 and its 200-day moving average price is $15.22. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.73 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after buying an additional 5,316 shares during the period. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after buying an additional 865 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Centessa Pharmaceuticals by 1,969.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company’s stock worth $2,173,000 after purchasing an additional 129,335 shares during the period. Lord Abbett & CO. LLC purchased a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at approximately $4,305,000. Finally, Franklin Resources Inc. lifted its holdings in Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after purchasing an additional 1,145,823 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on CNTA shares. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim increased their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.